Prognostic value of immune gene-expression signatures (iGES) vs. tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: a combined analysis of CALGB 40601 (Alliance) and PAMELA trials.
- Citation:
- Annals of Oncology vol 32 (suppl_5) 120MO, p 409 S407-S446
- Meeting Instance:
- ESMO 2021
- Year:
- 2021
- Type:
- Abstract
- Sub type:
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- GlaxoSmithKline
- Grants:
- U10CA180821, U10CA180882, U24CA196171; NCI SPORE (P50-CA58823), R01-CA229409, Instituto de Salud Carlos III - PI16/00904
- Corr. Author:
- Authors:
- Aranzazu Fernandez-Martinez Tomás Pascual Baljit Singh Paolo Nuciforo Katherine A. Hoadley Naim U. Rashid Patricia A. Spears Ian Krop David Hillman Ann Partridge Aleix Prat Lisa Carey Charles Perou
- Networks:
- LAPS-CT018, LAPS-MA036, LAPS-NC007
- Study
- CALGB-40601
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: